American Research Corporation at Texas Liver Institute

San Antonio, Texas 78215

2 studies enrolling now · 17 studies all time

What they study most

Chronic Hepatitis B, Healthy, Hepatic Impairment, Hepatic Insufficiency, Hepatitis C Virus Infection, Liver Cirrhosis, Biliary, Liver Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease, Non Alcoholic Steatohepatitis (NASH), Non-Alcoholic Steatohepatitis (NASH), Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis (NASH)

Studies at this site

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia — Recruiting now
• A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension — Completed
• Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection — Running, not enrolling
• A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function — Running, not enrolling
• A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function — Completed
• A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants — Completed
• A Study of LY3437943 in Participants With Impaired and Normal Liver Function — Completed
• Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) — Stopped early
• Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. — Stopped early
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function — Completed
• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis — Stopped early
• ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) — Completed
• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Completed
• Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis — Completed
• Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 — Completed